Trujillo H, Manotas R, Ramirez J I, Uribe A, Agudelo N, Zapata C T, Zuluaga A I, de Vidal E L
J Int Med Res. 1978;6(4):257-65. doi: 10.1177/030006057800600402.
Amikacin was used in the treatment of various Gram-negative infections in sixty-six children ranging in age from two days to thirteen years. Over 72% of the infections treated were classified as severe and the remainder were moderate. Among infections in which the site of origin was the urinary or gastro-intestinal tract, amikacin achieved thirty-eight (95%) complete or partial cures in forty patients. In respiratory tract infections, amikacin completely or partially cured six (75%) out of eight patients. The remaining eighteen infections involved skin, soft tissue and other miscellaneous categories in which amikacin therapy resulted in seventeen (94%) complete or partial cures. Overall, amikacin achieved fifty-four complete cures and seven clinical or bacteriological cures in sixty-six patients, which represents an 82% complete cure rate and 10% partial cure rate for all the patients in the study.
阿米卡星用于治疗66名年龄从2天至13岁的儿童的各种革兰氏阴性菌感染。所治疗的感染中超过72%被分类为严重感染，其余为中度感染。在起源部位为泌尿生殖道或胃肠道的感染中，阿米卡星在40名患者中实现了38例（95%）完全或部分治愈。在呼吸道感染中，阿米卡星在8名患者中完全或部分治愈了6例（75%）。其余18例感染涉及皮肤、软组织和其他杂类，其中阿米卡星治疗导致17例（94%）完全或部分治愈。总体而言，阿米卡星在66名患者中实现了54例完全治愈和7例临床或细菌学治愈，这代表了该研究中所有患者82%的完全治愈率和10%的部分治愈率。
